4Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patints with advanced non-small-cell lung cancer[J].J Clin Oncol,2003,21:2237. 被引量：1
5Herbst RS,Kies MS.ZDl839(Iressa)in non small cell lung cancer[J].Oncologist,2002,7(Suppl 4):9. 被引量：1
6Kris MG,Natale RB,Herbst RS,et al.A phase Ⅱ trial of ZDl839('Iressa')in advanced non-small cell lung cancer(NSCLC)patinenfs who had failed platinum-and docetaxel-based regimens(IDEAL 2)[J].Proceedings of ASCO,2002,21:292a,Abstract 1166. 被引量：1
7Shan NT,Kris MG,Pao W,et al.Practical management of Patients with non small-cellLung cancer treated with gefitinib[J].J Clin Oncol,2005,23(1):165. 被引量：1
8Okamoto I,Fujii K,Matsumoto M,et al.Diffuse alveolar damage after ZDl839 therapy in a patient with non-small cell lung cancer[J].hung Cancer,2003,40(3):339. 被引量：1
9Tamura K,Yamamoto N,TakedaK,et al.Am epidemiological sur vey for interstitial lung disease induced by gefitinib in patients with advanced nonsmall cell lung cancer.West Japan Thoracic Oncology Group(WJTOG)[J].Eur J Cancer,2003,1(5):S21. 被引量：1
1[1]Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target - based anticancer agents[J]. Drugs ,2000,60(Suppl) :S1 - S14. 被引量：1
2[2]Hanahan D, Weinberg RA. The hallmarks of cancer [ J ]. Cell,2000,100(1 ): 57 - 70. 被引量：1
3[3]Baselga J. New therapeutic agents targeting the epidermal growth factor receptor[J]. J Clin Oncol,2000,18(Suppl 21) :S54 - S59. 被引量：1
4[4]Wells A. EGF receptor[J]. Int J Biochem Cell Biol, 1999,31(6): 637 - 643. 被引量：1
5[5]Sako Y, Minoghchi S, Yanagida T. Single-molecule imaging of EGFR signaling on the surface of living cell [J ]. Nat Cell Biol,2002,2(3): 168 - 172. 被引量：1
6[6]Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions[ J ]. FEBS Lett, 1997,410 ( 1 ): 83 - 86. 被引量：1
7[7]Riese DJ, Stem DF. Specificity within the EGF family/ErbB receptor family signaling network[ J ]. BioasSays, 1998,20( 1 ) :41 - 48. 被引量：1
8[8]Ciardiello F, Caputo R, Bianco R et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD 1839(Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor[ J ]. Clin Cancer Res, 2001,7(10): 1459 - 1465. 被引量：1
9Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA,2003,290(16): 2149-2158. 被引量：1
10Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ,1995,311(7010): 899-909. 被引量：1
